¼¼°èÀÇ e-ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀå
e-Clinical Trial Technologies
»óǰÄÚµå : 1514161
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 204 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ e-ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀåÀº 2030³â±îÁö 311¾ï ´Þ·¯¿¡ µµ´Þ

2023³â¿¡ 131¾ï ´Þ·¯·Î Æò°¡µÈ ¼¼°èÀÇ e-ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀåÀº 2030³â¿¡´Â 311¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 13.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS)Àº CAGR 13.7%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 99¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀüÀÚ µ¥ÀÌÅÍ Ä¸Ã³(EDC) ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 13.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 36¾ï ´Þ·¯, Áß±¹Àº CAGR 12.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ e-ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀåÀº 2023³â 36¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 48¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023³âºÎÅÍ 2030³â±îÁö CAGRÀº 12.4%·Î Àü¸ÁµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 11.4%¿Í 10.9%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 9.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ e-ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀå-ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎÀÇ Á¤¸®

ÀÇÇÐÀÇ Áøº¸ ¹× Ä¡·á¹ýÀÇ ¹ß°ß¿¡ À־ ¸Å¿ì Áß¿äÇÑ ÀÓ»ó½ÃÇèÀº ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ Å« ÁøÈ­¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î ¼öÀÛ¾÷°ú Á¾ÀÌ ±â¹Ý ÇÁ·Î¼¼½º´Â ¿À·ù¿Í ºñÈ¿À²À» ÃÊ·¡ÇÒ ¼ö ÀÖ¾úÁö¸¸, µðÁöÅÐ ±â¼úÀÇ µµÀÔÀº ÀÌ ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ¾÷¹« È¿À²¼º°ú µ¥ÀÌÅÍ ¹«°á¼ºÀ» ¸ðµÎ Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ º¯È­´Â eClinical ¼Ö·ç¼Ç(ÀÓ»ó½ÃÇèÀÇ ´Ù¾çÇÑ Ãø¸éÀ» °£¼ÒÈ­Çϱâ À§ÇØ ¼³°èµÈ µðÁöÅÐ µµ±¸)ÀÇ °³¹ß ¹× µµÀÔ¿¡ ±¸ÇöµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼Ç¿¡´Â ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý(EDC) ½Ã½ºÅÛ, ÀüÀÚ »ç·Ê º¸°í¼­(eCRF), ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS), ¹«ÀÛÀ§È­ ¹× ÀÓ»ó½ÃÇè °ø±Þ °ü¸®(RTSM), ÀüÀÚ È¯ÀÚ º¸°í °á°ú(ePRO) µî Æ÷ÇԵ˴ϴÙ. °¢ ±¸¼º ¿ä¼Ò´Â °¢°¢ °íÀ¯ÇÑ ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. EDC ½Ã½ºÅÛÀº ½Ç½Ã°£ ÀÔ·Â ¹× °ËÁõÀ» ÅëÇØ µ¥ÀÌÅÍÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۰í, eCRF´Â º¹ÀâÇÑ Á¾ÀÌ ¾ç½ÄÀ» äÅÃÇÏ¿© ´ë½Å µ¥ÀÌÅÍÀÇ ½Å·Ú¼º°ú À¯¿¬¼ºÀ» Çâ»ó½Ã۰í, CTMS ±×¸®°í RTSM ½Ã½ºÅÛÀºº¸´Ù È¿°úÀûÀÎ ½ÃÇè °ü¸®¿Í ¹°·ù¸¦ ÃËÁøÇÕ´Ï´Ù.

ÀÓ»ó½ÃÇè¿¡¼­ ÇöÀúÇÑ µ¿ÇâÀº ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)À¸·ÎÀÇ À̵¿ÀÔ´Ï´Ù. DCT´Â ±â¼úÀ» Ȱ¿ëÇÏ¿© ±âÁ¸ÀÇ ÀÓ»ó½ÃÇè Áß½ÉÀÇ Á¢±Ù ¹æ½Ä¿¡¼­ º¸´Ù À¯¿¬Çϰí ȯÀÚ Áß½ÉÀÇ Àü·«À¸·Î ÀüȯÇÕ´Ï´Ù. ÀÌ ½ÃÇÁÆ®´Â µ¥ÀÌÅÍ Ç°ÁúÀ» Èñ»ýÇÏÁö ¾Ê°í ¿ø°Ý µ¥ÀÌÅÍ ¼öÁý ¹× ȯÀÚ Âü¿©¸¦ °­È­ÇÒ ¼ö ÀÖ´Â µðÁöÅÐ °Ç°­ ±â¼ú(DHT)¿¡ ÀÇÇØ Å©°Ô Áö¿øµË´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ÀÌ·¯ÇÑ ÀüȯÀ» Àû±ØÀûÀ¸·Î Áö¿øÇϸç ȯÀÚÀÇ ¾ÈÀü¼º°ú µ¥ÀÌÅÍ ¹«°á¼ºÀ» ÃÖ¿ì¼±À¸·Î Çϱâ À§ÇÑ ÁöħÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÁöħÀº ÀüÀÚ Á¤º¸ Äܼ¾Æ®(eConsent), ¿ø°Ý ÀÇ·á ¹æ¹® ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀÇ »ç¿ëÀ» ÃßÁøÇϸç, À̵éÀº DCTÀÇ È¿°úÀûÀÎ ±¸Çö¿¡ ÇʼöÀûÀÔ´Ï´Ù. DCT¿¡ eClinical ±â¼úÀ» ÅëÇÕÇÏ´Â °ÍÀº ºñÁî´Ï½º È¿À²¼º»Ó¸¸ ¾Æ´Ï¶ó º¹ÀâÇÑ ±ÔÁ¦ ¿ä±¸ »çÇ×À» ÁؼöÇÏ°í ¸ðµç ±â¼ú µµÀÔÀÌ ¹ýÀû ¹× À±¸®Àû ±âÁØÀ» ÃæÁ·ÇÏ´ÂÁö È®ÀÎÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

eClinical ÀÓ»ó½ÃÇè ±â¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÃËÁøµË´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø °­È­·Î ÄÄÇöóÀ̾𽺸¦ È®º¸Çϰí ÀÓ»ó ¾÷¹«¸¦ °£¼ÒÈ­Çϱâ À§ÇØ µðÁöÅÐ ¼Ö·ç¼ÇÀ» »ç¿ëÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®, ÀΰøÁö´É ¹× ¸Ó½Å·¯´×ÀÇ ±â¼úÀû Áøº¸´Â eClinical ½Ã½ºÅÛÀÇ ±â´ÉÀ» Áö¼ÓÀûÀ¸·Î Çâ»ó½ÃÄÑ º¹ÀâÇÑ µ¥ÀÌÅÍ Ã³¸® ¹× ¿¹Ãø ºÐ¼®¿¡ ´ëÇÑ ´ëÀÀ ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. COVID-19ÀÇ ´ëÀ¯Çà ½Ã ±ÞÁõÇÑ ºÐ»ê ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä´Â ÆíÀǼº°ú ȯÀÚ ºÎ´ã °¨¼Ò¸¦ Áß½ÃÇÏ´Â °Ç°­ °ü¸®¿¡¼­ ȯÀÚ Á᫐ Á¢±Ù¹ý¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ º¯È­¸¦ ¹Ý¿µÇÕ´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇèÀÇ ¼¼°èÈ­´Â ¸ÖƼ»çÀÌÆ®, ´Ù±¹Àû½ÃÇèÀ» È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â °ß°íÇϰí ÀûÀÀ¼ºÀÌ ³ôÀº eClinical ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎ ¿Ü¿¡µµ µðÁöÅÐ ½Ã´ëÀÇ µ¥ÀÌÅÍ º¸¾È°ú ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö°í ÀÇ·áºñ Àý°¨À̶ó´Â °æÁ¦Àû ¾Ð·ÂÀÌ ¾ÈÀüÇÏ°í ºñ¿ë È¿À²ÀûÀÎ eClinical ±â¼úÀÇ Çʿ伺À» °­Á¶ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼Ò´Â Á¾ÇÕÀûÀ¸·Î eClinical ¼Ö·ç¼ÇÀÇ µµÀÔ°ú °³¼±À» ÃËÁøÇϰí ÀÓ»ó ¿¬±¸ ºÐ¾ß¿¡¼­ Áß¿äÇÑ Áøº¸¸¦ º¸¿©ÁÝ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 64°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global e-Clinical Trial Technologies Market to Reach US$31.1 Billion by 2030

The global market for e-Clinical Trial Technologies estimated at US$13.1 Billion in the year 2023, is expected to reach US$31.1 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. Clinical Trial Management Systems (CTMS), one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$9.9 Billion by the end of the analysis period. Growth in the Electronic Data Capture (EDC) segment is estimated at 13.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 12.4% CAGR

The e-Clinical Trial Technologies market in the U.S. is estimated at US$3.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.4% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global e-Clinical Trial Technologies Market - Key Trends and Drivers Summarized

Clinical trials, pivotal in advancing medical science and treatment discovery, have experienced substantial evolution driven by technological advancements. Traditionally hindered by manual, paper-based processes prone to errors and inefficiencies, the introduction of digital technologies has revolutionized this field, enhancing both operational efficiency and data integrity. This transformation is embodied in the development and adoption of eClinical solutions—digital tools designed to streamline various trial aspects. These solutions include Electronic Data Capture (EDC) systems, Electronic Case Report Forms (eCRFs), Clinical Trial Management Systems (CTMS), Randomization and Trial Supply Management (RTSM), and Electronic Patient-Reported Outcomes (ePRO). Each component contributes uniquely: EDC systems improve data accuracy through real-time entry and validation, eCRFs replace cumbersome paper forms enhancing data reliability and flexibility, and CTMS and RTSM systems facilitate more effective trial management and logistics.

A notable trend within clinical trials is the shift towards decentralized clinical trials (DCTs), which leverage technology to move from traditional site-centric approaches to more flexible, patient-centered strategies. This shift is largely supported by digital health technologies (DHTs) that allow for remote data collection and enhanced patient engagement without sacrificing data quality. The U.S. Food and Drug Administration (FDA) has actively supported this transition, providing guidelines to ensure patient safety and data integrity remain paramount. These guidelines promote the use of electronic informed consent (eConsent), telehealth visits, and remote monitoring, which are crucial for the effective execution of DCTs. The integration of eClinical technologies into DCTs is essential not only for operational efficiency but also for adhering to complex regulatory requirements, ensuring that every technological adoption aligns with legal and ethical standards.

The growth of the eClinical trial technologies market is propelled by several key factors. Enhanced regulatory support encourages the use of digital solutions to ensure compliance and streamline clinical operations. Technological advancements in data analytics, artificial intelligence, and machine learning continuously improve the functionalities of eClinical systems, making them more capable of handling complex data processes and predictive analytics. The demand for decentralized trials, which surged during the COVID-19 pandemic, reflects a broader shift towards patient-centric approaches in healthcare, emphasizing convenience and reduced patient burden. Furthermore, the globalization of clinical trials necessitates robust, adaptable eClinical solutions capable of managing multi-site, multinational trials efficiently. Alongside these drivers, increasing concerns over data security and privacy in the digital age, coupled with economic pressures to reduce healthcare costs, underscore the need for secure, cost-effective eClinical technologies. These elements collectively enhance the adoption and refinement of eClinical solutions, marking a significant advancement in the field of clinical research.

Select Competitors (Total 64 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â